Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
No report run on this ticker yet
Only preliminary foundational data below
Sign in to run a fresh report
Free · results in ~10 min
For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Teva Pharmaceutical Industries Ltd. (TEVA) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Healthcare · Drug Manufacturers - Specialty & Generic
Tel Aviv-Yafo, 6944020, Israel
tevapharm.com
Price
$36.14
Market Cap
$42.1B
Employees
31,173
Beta
0.88
Avg Volume
5,184,807
Last Dividend
$0.85
CEO
Mr. Richard D. Francis
Teva Pharmaceutical Industries Ltd. ADR represents shares of an Israeli-based global pharmaceutical company focused on developing, manufacturing, and marketing medicines across multiple therapeutic areas. Teva is widely recognized for its large portfolio of generic drugs, which provide cost-effective alternatives to branded treatments and support healthcare systems in controlling medication expenditure. Alongside generics, Teva offers specialty and biopharmaceutical products in fields such as central nervous system disorders, respiratory conditions, oncology, and other chronic diseases. The company serves hospitals, pharmacies, healthcare providers, and wholesalers across North America, Europe, and a broad range of international markets through regionally organized business segments. Teva also engages in the sale of active pharmaceutical ingredients and provides contract manufacturing services, reinforcing its role in the wider pharmaceutical supply chain. Founded in 1901 and headquartered in Tel Aviv, Israel, Teva Pharmaceutical Industries Ltd. ADR gives investors exposure to one of the world’s leading players in generic and branded pharmaceutical products.
Runs with full report
Earnings Schedule
Checked daily · calendar updated Aug 10 No upcoming print on the calendar yet — companies typically confirm a few weeks ahead. Last print was Jul 29, 2026.
EPS surprise history — vs analyst consensus · 4 prints of vendor history
+16.4%
Nov '25
+16.1%
Jan '26
+15.2%
Apr '26
-81.8%
Jul '26
| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Jul 29, 2026 | $0.11 | $0.02 -81.8% | — | — |
| Apr 29, 2026 | $0.46 | $0.53 +15.2% | — | — |
| Jan 23, 2026 | $1.61 | $1.87 +16.1% | — | — |
| Nov 5, 2025 | $0.67 | $0.78 +16.4% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Aug 10, 2026 | 4 | View |
| Aug 5, 2026 | 4 | View |
| Aug 5, 2026 | 4 | View |
| Aug 3, 2026 | 144 | View |
| Aug 3, 2026 | 144 | View |
| Jul 29, 2026 | F-6 POS | View |
| Jul 29, 2026 | 10-Q | View |
| Jul 29, 2026 | 8-K | View |
| Jun 22, 2026 | 4 | View |
| Jun 18, 2026 | 144 | View |
| Jun 16, 2026 | 4 | View |
| Jun 11, 2026 | 144 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 11, 2026 10:55am (just now)
Current data · timestamped when a report runs
$36.58
Change · Aug 11
+0.44 (+1.22%)
Day Range
$36.15 – $36.98
52-Week Range
$16.26 – $37.35
50-Day MA
$33.40
200-Day MA
$31.27
Volume
115,076.00
Share Structure
Outstanding
1,165,296,084.00
Float
1,055,536,846.00
Free Float
90.6%
High free float
— 90.6% of shares trade freely, ~9.4% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
TD Twelve Data statement
HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEXStock Price / EPS (Diluted)
29.87
Stock Price: $36.14
EPS (Diluted): 1.21
EPS (Diluted): 1.21
P/B Ratio (Price vs net asset value)
HEXStock Price / Book Value Per Share
5.31
Stock Price: $36.14
Total Equity: $7.91B
Shares: 1,163,000,000
Total Equity: $7.91B
Shares: 1,163,000,000
EV/EBITDA (Total value vs operating profit)
HEXEnterprise Value / EBITDA
12.78
Market Cap: $42.11B
Total Debt: $1.82B
Cash: $3.56B
EBITDA: $3.16B
Total Debt: $1.82B
Cash: $3.56B
EBITDA: $3.16B
Enterprise Value (Takeover price (cap + debt - cash))
HEXMarket Cap + Total Debt - Cash
$40.4B
Market Cap: $42.11B
Total Debt: $1.82B
Cash: $3.56B
Total Debt: $1.82B
Cash: $3.56B
Gross Margin (Revenue left after direct costs)
HEXGross Profit / Revenue
51.8%
Gross Profit: $8.94B
Revenue: $17.26B
Revenue: $17.26B
Operating Margin (Revenue left after all operations)
HEXOperating Income / Revenue
12.5%
Operating Income: $2.16B
Revenue: $17.26B
Revenue: $17.26B
Net Margin (Revenue left as actual profit)
HEXNet Income / Revenue
8.2%
Net Income: $1.41B
Revenue: $17.26B
Revenue: $17.26B
ROE (Profit from shareholder equity)
HEXNet Income / Total Equity
17.8%
Net Income: $1.41B
Total Equity: $7.91B
Total Equity: $7.91B
ROIC (Profit from all invested capital)
HEXNOPAT / Invested Capital
40.1%
Operating Income: $2.16B
Tax Rate: -14.7%
Equity: $7.91B
Total Debt: $1.82B
Cash: $3.56B
Tax Rate: -14.7%
Equity: $7.91B
Total Debt: $1.82B
Cash: $3.56B
Current Ratio (Can it pay short-term bills)
HEXCurrent Assets / Current Liabilities
1.04
Current Assets: $13.95B
Current Liabilities: $13.46B
Current Liabilities: $13.46B
Debt/Equity (Leverage — debt vs equity)
HEXTotal Debt / Total Equity
0.23
Short-Term Debt: $1.82B
Long-Term Debt: $0.00
Total Debt: $1.82B
Total Equity: $7.91B
Long-Term Debt: $0.00
Total Debt: $1.82B
Total Equity: $7.91B
Rev/Share (Top-line per share)
HEXRevenue / Shares Outstanding
$14.84
Revenue: $17.26B
Shares: 1,163,000,000
Shares: 1,163,000,000
Book Value/Share (Net assets per share)
HEX(Total Assets - Total Liabilities) / Shares
$6.80
Total Equity: $7.91B
Shares: 1,163,000,000
Shares: 1,163,000,000
FCF/Share (Real cash generated per share)
HEX(Operating Cash Flow + CapEx) / Shares
$0.99
Operating CF: $1.65B
CapEx: -$501.00M
Shares: 1,163,000,000
CapEx: -$501.00M
Shares: 1,163,000,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TDLast Annual Dividend / Stock Price
2.4%
Last Dividend: $0.85
Stock Price: $36.14
Stock Price: $36.14
Payout Ratio (Earnings paid out as dividends)
HEXDividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $1.41B
Net Income: $1.41B
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Aug 7, 2026 4:37am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $15.9B | $14.9B | $15.8B | $16.5B | $17.3B |
| Cost of Revenue | $8.3B | $8.0B | $8.2B | $8.5B | $8.3B |
| Gross Profit | $7.6B | $7.0B | $7.6B | $8.1B | $8.9B |
| Operating Expenses | $5.9B | $9.1B | $7.2B | $8.4B | $6.8B |
| Operating Income | $1.7B | -$2.1B | $433.0M | -$303.0M | $2.2B |
| Net Income | $417.0M | -$2.4B | -$559.0M | -$1.6B | $1.4B |
| EBITDA | $3.0B | -$791.0M | $1.6B | $756.0M | $3.2B |
| EPS | $0.38 | $-2.12 | $-0.50 | $-1.45 | $1.23 |
| EPS (Diluted) | $0.38 | $-2.12 | $-0.50 | $-1.45 | $1.21 |
Balance Sheet (Annual)
Last updated: Aug 7, 2026 4:37am (4d ago)| Metric | 2023 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $3.2B | $3.3B | $3.6B |
| Total Current Assets | — | — | $12.5B | $12.6B | $13.9B |
| Total Assets | $43.1B | $42.1B | $43.5B | $39.3B | $40.7B |
| Current Liabilities | — | — | $12.2B | $12.8B | $13.5B |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $35.5B | $34.7B | $35.4B | $33.6B | $32.8B |
| Total Equity | $7.6B | $7.4B | $8.1B | $5.7B | $7.9B |
| Retained Earnings | -$14.1B | -$14.0B | -$13.5B | -$15.2B | -$13.8B |
Cash Flow (Annual)
Last updated: Aug 7, 2026 4:37am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $798.0M | $1.6B | $1.4B | $1.2B | $1.6B |
| Capital Expenditure | -$562.0M | -$548.0M | -$526.0M | -$498.0M | -$501.0M |
| Free Cash Flow | $236.0M | $1.0B | $842.0M | $749.0M | $1.1B |
| Acquisitions (net) | $0 | -$7.0M | $0 | -$15.0M | $0 |
| Net Debt Issued / (Repaid) | -$6.6B | -$1.4B | -$4.2B | -$1.6B | -$4.1B |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | $21.0M | $636.0M | $393.0M | $74.0M | $256.0M |
Growth Trends (YoY %)
Last updated: Aug 7, 2026 4:37am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -6.0% | +6.2% | +4.4% | +4.3% |
| Gross Profit Growth | -8.2% | +9.6% | +5.5% | +10.8% |
| Operating Income Growth | -222.3% | +120.6% | -170.0% | +811.9% |
| Net Income Growth | -664.3% | +76.2% | -193.2% | +186.0% |
| EBITDA Growth | -126.0% | +300.5% | -52.3% | +317.9% |
Dividend History (Last 20)
Last updated: Aug 10, 2026 10:20pm (12h ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2017-11-27 | $0.09 | — | — | — |
| 2017-08-25 | $0.07 | — | — | — |
| 2017-06-01 | $0.29 | — | — | — |
| 2017-02-28 | $0.29 | — | — | — |
| 2016-12-01 | $0.29 | — | — | — |
| 2016-08-18 | $0.29 | — | — | — |
| 2016-05-20 | $0.29 | — | — | — |
| 2016-02-25 | $0.29 | — | — | — |
| 2015-11-13 | $0.29 | — | — | — |
| 2015-08-18 | $0.29 | — | — | — |
| 2015-05-15 | $0.29 | — | — | — |
| 2015-02-17 | $0.29 | — | — | — |
| 2014-11-13 | $0.27 | — | — | — |
| 2014-08-19 | $0.29 | — | — | — |
| 2014-05-16 | $0.30 | — | — | — |
| 2014-02-20 | $0.29 | — | — | — |
| 2013-11-18 | $0.28 | — | — | — |
| 2013-08-16 | $0.27 | — | — | — |
| 2013-05-16 | $0.27 | — | — | — |
| 2013-02-19 | $0.27 | — | — | — |
Industry Benchmarks
Compares TEVA against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for TEVA — it's generated by the pipeline (
market-narrative step).
Claude Reading
No AI findings yet for TEVA — they're generated by the
pipeline (
ai-findings step) when a report is run on this ticker.
GPT Reading
No GPT reading yet for TEVA — it's generated by the
pipeline (
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
No Grok reading yet for TEVA — it's generated by the
pipeline (
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · four lenses
No community reviews yet for TEVA.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.525 · a5aac093 · 2026-08-10 20:52:14